A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian–human immunodeficiency virus infection
| Autor: | Claudine Bruck, Neil Almond, M. Deschamps, P. J. F. Ten Haaft, Jim Stott, Willy M. J. M. Bogers, D. Labbe, P. Momin, P. Van Der Meide, Petra Mooij, P. Von Hoegen, Jonathan L. Heeney, M. Van Der Kolk, Gerald Voss |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Immunology
Antibody Affinity Simian Acquired Immunodeficiency Syndrome HIV Infections HIV Antibodies HIV Envelope Protein gp120 Biology medicine.disease_cause Polymerase Chain Reaction Virus Immune system Neutralization Tests Immunity In vivo medicine Animals Immunology and Allergy AIDS Vaccines Immunity Cellular Vaccines Synthetic Chimera Vaccination Simian immunodeficiency virus Vaccine efficacy Macaca mulatta Virology Infectious Diseases HIV-1 Simian Immunodeficiency Virus |
| Zdroj: | AIDS. 12:F15-F22 |
| ISSN: | 0269-9370 |
| DOI: | 10.1097/00002030-199805000-00002 |
| Popis: | Objectives: To investigate whether immunization with recombinant HIV-1 envelope protein derived from a clinical isolate could protect macaques from infection with an in vivo passaged chimeric simian-human immunodeficiency virus (SHIV). Design and methods: A total of 16 animals were studied from which three groups of four animals were immunized with vaccine formulations of the CC-chemokine receptor-5-binding recombinant gp120 of HIV-1 W6.1D . Four weeks after the last immunization, all 16 animals were intravenously challenged with in vivo passaged SHIV derived from the same HIV-1 group B clinical isolate (W6.1 D) as the vaccines. Results: Vaccine protection from infection was demonstrated in 10 out of 12 macaques immunized with recombinant gp120. Complete protection from infection was achieved with all of the animals that received the SBAS2-W6.1 D formulation, a potent inducer of both T-cell and humoral immune responses. Partial protection was achieved with SBAS1-W6.1 D, a formulation based on immunomodulators known to induce T-cell responses in humans. In vaccinated animals that were infected, virus load was reduced and infection was delayed. Conclusions: In a relatively large number of primates, vaccine efficacy was demonstrated with a clinically relevant HIV-1 vaccine. These results reveal that it is possible to induce sterilizing immunity sufficient to protect from infection with SHIV which was passaged multiple times in vivo. Our findings have implications for current HIV-1 clinical vaccine trials and ongoing efforts to develop safe prophylactic AIDS vaccines. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|